Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects nerve cells in the brain and ...

The ALS market is witnessing robust growth driven by increased disease awareness, advancements in genetic research, and an expanding pipeline of ther ...

KLTO‑202 is an experimental gene therapy that would deliver the instructions for a protein that may reduce inflammation and ...

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to a new gene therapy for Amyotrophic Lateral ...

Documenting his experiences has proven to be the outlet Darin Nakakihara needs in the wake of his ALS diagnosis.

BrainStorm Cell Therapeutics issued a statement Tuesday supporting a Citizens’ Petition submitted to the FDA requesting the ...

The Longitude Prize on ALS has launched to find AI-based approaches to help transform treatment of amyotrophic lateral sclerosis (ALS).

Matt Keil, who was the bassist of Canadian band Comeback Kid before becoming a realtor in the Twin Cities, has died following ...

Explore Our Free-Market Analysis Sample – Instant Access: – https://www.astuteanalytica.com/request-sample/amyotrophic-lateral-sclerosis-treatment-market ...

The U.S. FDA has granted orphan drug designation to Klotho Neurosciences Inc.’s secreted-Klotho (s-KL) promoter, gene and ...

The treatment, licensed to Klotho Neurosciences, is based on a technology developed at the Universitat Autònoma de Barcelona (UAB).

US FDA grants orphan drug designation to Klotho Neurosciences’ KLTO-202 to treat amyotrophic lateral sclerosis: New York Saturday, July 12, 2025, 15:00 Hrs [IST] Klotho Neurosci ...